No information exists in the literature regarding the effect of mRNA SARS-CoV-2 vaccine on subsequent IVF cycle attempt. We therefore aim to assess the influence of mRNA SARS-CoV-2 vaccine on IVF treatments.
Featured Article: Does mRNA SARS-CoV-2 vaccine influence patients' performance during IVF-ET cycle?
Articles
-
-
Estrogen-sensitive activation of SGK1 induces M2 macrophages with anti-inflammatory properties and a Th2 response at the maternal–fetal interface
-
Artificial ovaries constructed from biodegradable chitin-based hydrogels with the ability to restore ovarian endocrine function and alleviate osteoporosis in ovariectomized mice
-
How much obesity and diabetes do impair male fertility?
-
Interindividual variation of progesterone elevation post LH rise: implications for natural cycle frozen embryo transfers in the individualized medicine era
-
Assessment of fetal intracranial pathologies first demonstrated late in pregnancy: cell proliferation disorders
-
Recurrent Implantation Failure-update overview on etiology, diagnosis, treatment and future directions
-
Molecular patterns of sex determination in the animal kingdom: a comparative study of the biology of reproduction
-
Role of oxidative stress in female reproduction
-
Estrogen in the adult male reproductive tract: A review
'On Health' blog
Aims and scope
Reproductive Biology and Endocrinology publishes and disseminates high-quality results from excellent research in the reproductive sciences.
The journal publishes on topics covering gametogenesis, fertilization, early embryonic development, embryo-uterus interaction, reproductive development, pregnancy, uterine biology, endocrinology of reproduction, control of reproduction, reproductive immunology, neuroendocrinology, and human reproductive medicine.
We will consider manuscripts examining non-human primates, rats, and mice if they inform the human condition. However, we will no longer review studies involving horses, dogs, sheep, cats, cows, pigs, birds, or fish.
Follow us on Twitter at @RBEJournal!
Editor profiles
Co-Editor-in-Chief, David B Seifer
David B. Seifer is a Professor of Obstetrics & Gynecology at Yale School of Medicine in the Division of Reproductive Endocrinology and Infertility at Yale New Haven Hospital Medical Center in New Haven, CT (USA). Dr. Seifer is a consultant for the Food and Drug Administration (USA) and has published over 150 medical studies in peer-reviewed journals.
His translational research has focused upon the biology of ovarian function, particularly the aging ovary. This research has resulted in a better understanding of normal and abnormal follicular development during ART and in identifying novel human ovarian growth factors (ie. neurotrophins, inhibin B and AMH) which inform the clinical practice of reproductive medicine. His clinical research has focused upon health care disparities among women with infertility and the role of vitamin D in female reproductive health and polycystic ovarian syndrome.
Co-Editor-in-Chief, Raoul Orvieto
Raoul Orvieto is a full professor of Obstetrics and Gynecology and incumbent of the Tarnesby-Tarnowski Chair for Family Planning and Fertility Regulation, at the Sackler Faculty of Medicine, Tel-Aviv University, Israel. Prof Orvieto is the director of the Division of Reproductive Endocrinology and Infertility, at the Sheba (Tel-Hashomer) Medical Center, Israel. He has been author and co-author of more than 200 publications in national and international journals. His scientific interests include various aspects of controlled ovarian hyperstimulation (COH). The role of GnRH-analogues, and specifically GnRH agonist versus antagonist in COH for IVF, pre-implantation genetic screening (PGS), triggering final follicular maturation and several aspects of ovarian hyperstimulation syndrome (OHSS): pathophysiology, prediction, prevention and its relation to the inflammatory response.
Annual Journal Metrics
-
Citation Impact
4.982 - 2-year Impact Factor (2021)
5.426 - 5-year Impact Factor (2021)
1.222 - Source Normalized Impact per Paper (SNIP)
1.065 - SCImago Journal Rank (SJR)
Speed
8 days to first decision for all manuscripts (Median)
35 days to first decision for reviewed manuscripts only (Median)Usage
1,556,901 Downloads (2022)
1,236 Altmetric mentions (2021)